Hepatitis C virus
Hepatitis C (HCV) virus infection is mostly chronic and can lead to the development of liver cirrhosis and hepatocellular carcinoma. The virus is highly heterogenous, and at least 6 major genotypes have been recognized, each with a large number of subtypes. The likelihood of a response to antiviral therapy is clearly associated with the HCV genotype, and genotyping is clinically important in choosing the appropriate HCV therapy. At present no effective vaccine is available, but multiple highly effective directly-acting antiviral agents have recently been developed.
DDL is an expert laboratory for the analysis of resistance-associated mutations in HCV and provides its support to many HCV DAA studies, involving numerous NS3, NS5A and NS5B inhibitors from more than 10 different sponsors.
Screening for mutations associated with resistance to antiviral therapy
Serum or EDTA plasma. Heparinized blood can not be used.
DDL has extensive and expanding experience in molecular diagnosis and characterization of respiratory infections.
Broad viral screening can be performed using e.g., the Luminex xTAG RVP FAST v2 assay, detecting: RSVA/B, influenza A (H1, H1pdm2009, H3), influenza B, parainfluenza (1-4), metapneumovirus, adenovirus, entero-rhinovirus, coronavirus (NL63, HKU1, 229E, OC43), bocavirus.